Teleflex (TFX) Downgraded by ValuEngine to Hold

Teleflex (NYSE:TFX) was downgraded by research analysts at ValuEngine from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Friday.

Several other brokerages have also recently weighed in on TFX. Zacks Investment Research raised Teleflex from a “hold” rating to a “buy” rating and set a $261.00 target price for the company in a research note on Tuesday, September 12th. BidaskClub downgraded Teleflex from a “hold” rating to a “sell” rating in a report on Tuesday, August 8th. Barclays reaffirmed an “overweight” rating and set a $253.00 target price (up from $230.00) on shares of Teleflex in a report on Tuesday, September 12th. Needham & Company LLC reaffirmed a “buy” rating on shares of Teleflex in a report on Friday, August 4th. Finally, Jefferies Group reaffirmed a “buy” rating and set a $253.00 target price (up from $230.00) on shares of Teleflex in a report on Wednesday, August 9th. One analyst has rated the stock with a sell rating, five have given a hold rating and six have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $274.44.

Shares of Teleflex (TFX) traded up $0.11 during mid-day trading on Friday, reaching $265.58. The company had a trading volume of 262,747 shares, compared to its average volume of 257,338. Teleflex has a fifty-two week low of $145.00 and a fifty-two week high of $271.23. The company has a market capitalization of $11,960.00, a PE ratio of 32.82, a P/E/G ratio of 2.27 and a beta of 1.05. The company has a debt-to-equity ratio of 0.88, a current ratio of 4.72 and a quick ratio of 3.70.

Teleflex (NYSE:TFX) last announced its earnings results on Thursday, November 2nd. The medical technology company reported $2.12 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.01 by $0.11. Teleflex had a return on equity of 16.27% and a net margin of 12.41%. The business had revenue of $534.70 million during the quarter, compared to analysts’ expectations of $522.94 million. During the same quarter last year, the business posted $1.80 earnings per share. The company’s quarterly revenue was up 17.3% on a year-over-year basis. sell-side analysts expect that Teleflex will post 8.35 EPS for the current year.

In other news, Director Stephen K. M.D. Klasko sold 200 shares of the company’s stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $241.88, for a total transaction of $48,376.00. Following the completion of the sale, the director now directly owns 8,080 shares of the company’s stock, valued at $1,954,390.40. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Corporate insiders own 2.39% of the company’s stock.

A number of institutional investors have recently made changes to their positions in TFX. Aperio Group LLC lifted its stake in Teleflex by 20.2% in the 2nd quarter. Aperio Group LLC now owns 13,028 shares of the medical technology company’s stock worth $2,707,000 after acquiring an additional 2,189 shares in the last quarter. Campbell & CO Investment Adviser LLC purchased a new stake in Teleflex in the 2nd quarter worth about $200,000. Shell Asset Management Co. lifted its stake in Teleflex by 66.0% in the 2nd quarter. Shell Asset Management Co. now owns 5,044 shares of the medical technology company’s stock worth $1,048,000 after acquiring an additional 2,005 shares in the last quarter. Great West Life Assurance Co. Can lifted its stake in Teleflex by 2.0% in the 2nd quarter. Great West Life Assurance Co. Can now owns 35,669 shares of the medical technology company’s stock worth $7,406,000 after acquiring an additional 698 shares in the last quarter. Finally, Rothschild Asset Management Inc. lifted its stake in Teleflex by 10.4% in the 2nd quarter. Rothschild Asset Management Inc. now owns 148,395 shares of the medical technology company’s stock worth $30,831,000 after acquiring an additional 13,932 shares in the last quarter. 89.26% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: “Teleflex (TFX) Downgraded by ValuEngine to Hold” was first reported by American Banking News and is the property of of American Banking News. If you are viewing this report on another publication, it was illegally copied and republished in violation of US and international copyright & trademark law. The correct version of this report can be accessed at https://www.americanbankingnews.com/2017/12/02/teleflex-tfx-downgraded-by-valuengine-to-hold.html.

Teleflex Company Profile

Teleflex Incorporated is a provider of medical technology products. The Company designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for diagnostic and therapeutic procedures in critical care and surgical applications. The Company operates through six segments: Vascular North America; Anesthesia North America; Surgical North America; Europe, the Middle East and Africa (EMEA); Asia, and Original Equipment Manufacturer (OEM).

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Teleflex (NYSE:TFX)

Receive News & Ratings for Teleflex Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply